In September 2017, the FDA approved GSK’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first dry powder inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This agent puts three COPD medications into one inhaler: a LAMA, a LABA and a corticosteroid. The dose is one inhalation once daily. View more prescribing information on Trelegy Ellipta here .
A 2009 review found that the evidence supporting the effectiveness of zinc is mixed with respect to cough,  and a 2011 Cochrane review concluded that zinc "administered within 24 hours of onset of symptoms reduces the duration and severity of the common cold in healthy people".  A 2003 review concluded: "Clinical trial data support the value of zinc in reducing the duration and severity of symptoms of the common cold when administered within 24 hours of the onset of common cold symptoms."  Zinc gel in the nose may lead to long-term or permanent loss of smell. The FDA therefore discourages its use.